Abstract Details

Title Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 282

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Jean Pelletier, MD, PhD (Dpt of Neurology, CHU Timone) PRESENTER	Dr. Pelletier has nothing to disclose.
Jean Philippe Ranjeva	No disclosure on file
Leah Shabo	No disclosure on file
Gilles Edan	Gilles Edan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Gilles Edan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Gilles Edan has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Gilles Edan has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck.
	No disclosure on file
	No disclosure on file
Bertrand Audoin	No disclosure on file
Audrey Rico Lamy (Hopital Timone Adultes)	No disclosure on file
Lydie Crespy	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Adil Maarouf	Adil Maarouf has nothing to disclose.
	No disclosure on file
Marie-Pierre Chaunu	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Rebecca M. Pruss, PhD (Trophos)	No disclosure on file
Wilfried Hauke	No disclosure on file

��ɫ����